Rebfon-DSR i.e. Rabeprazole Sodium and Domperidone capsule uses are very broad in several spasmodic conditions like GERD, gas in the stomach, acid formation, and ulcers. Gastroesophageal Reflux Disease (GERD) is a condition where stomach acid flows back into the esophagus, which can cause irritation and inflammation. Later on, it can cause symptoms such as heartburn, regurgitation, trouble swallowing, and chest pain. The worst complications of GERD are such as esophagitis, Barrett esophagus, and esophageal cancer.
Table of Contents
Rabeprazole Sodium and Domperidone SR capsules are two molecule medications that are used to treat gastroesophageal reflux disease (GERD). Rabeprazole is a proton pump inhibitor (PPI) that blocks the production of acid in the stomach. Domperidone is a prokinetic agent, that enhances the movement of food through the stomach and large intestines.
Role of Proton Pump Inhibitors (PPIs) in Acid Suppression:
Rabeprazole Sodium: An Overview of PPIs:
Rabeprazole Sodium is a proton inhibitor that is used to control the acid in the stomach. It is very effective in GERD and peptic ulcer disease. It blocks the production of acid in the stomach. Rabeprazole Sodium was approved as a new PPI in 1999 by the FDA.
Rabeprazole is a prescription medicine in the form of Capsules, tablets, and Powder for Injection. It is usually taken once daily in the morning before a meal. It has some side effects like diarrhea, nausea, and headache.
It is more effective than Omeprazole, and well tolerated than other PPIs with lower side effects.
Mechanism of Action of Rabeprazole Sodium:
Rabeprazole Sodium is able to inhibit the gastric H+/K+ -ATPase enzyme. It is also known as the proton pump that secretes acid into the stomach. It is a prodrug that activates the acidic environment of the parietal cells. Here, it forms a covalent bond with the proton pump, and also irreversible blocks its activity. This whole process provides a sustained suppression of gastric acid secretion, therefore, it helps treat acid disorders such as GERD and stomach ulcers.
Efficacy and Safety of Rabeprazole Sodium in GERD Management:
Rabeprazole Sodium is a PPI that is used to treat gastroesophageal reflux disease (GERD). Usually, PPIs block the production of stomach acid. It helps to relieve GERD symptoms.
It shows effectiveness in treating GERD in a number of clinical studies. In a recent study, Rabeprazole was found more effective than a placebo in heartburn and reflux symptoms in GERD patients. It was also found as effective as PPIs like Omeprazole and Lansoprazole in healing erosive esophagitis.
It is considered to be safe in general conditions. It has some common side effects are headache, diarrhea, and nausea.
The efficacy and safety of Rabeprazole Sodium in the long-term management of GERD has been studied. Rabeprazole was found effective in preventing the recurrence of GERD symptoms in patients who have used other PPIs like Omeprazole and Lansoprazole.
Rabeprazole Sodium is a proton pump inhibitor (PPI) that is known as an effective medicine in gastroesophageal reflux disease (GERD). It is a model drug for symptoms like stomach acid backup into the esophagus, heartburn, and acid indigestion.
It is effective in relieving the symptoms of GERD. It is more effective than conventional PPIs such as Omeprazole. It is also better tolerated than some other PPIs with fewer side effects.
Enhancing Gut Motility with Domperidone
Domperidone sustained release is a long-acting formulation of this drug. It increases the movement and contractions of the stomach and bowel. It is also used to treat Gastroparesis which is a problem where the stomach does not empty properly. Some other symptoms are also treated with domperidone such as Reflux esophagitis, Nausea and vomiting, and Inability to burp.
Domperidone SR: Introducing a Motility-Enhancing Agent:
Domperidone SR is slow-release mechanism formulation of domperidone. It belongs to the class of dopamine antagonists. Domperidone SR is used as a motility-enhancing agent, it increases the movement of the stomach and upper gastrointestinal (GI) tract. It also has antiemetic effects which prevent nausea and vomiting symptoms by blocking dopamine receptors in the brain.
How Domperidone Acts on Gastrointestinal Motility:
Domperidone is a medicine that has the ability to improve digestion. It increases the movements of the stomach and bowel. It is used for the treatment of several conditions, such as gastroparesis, reflux esophagitis, nausea and vomiting, and inability to burp. Usually, domperidone does not cross the blood-brain barrier, thus it does not have the same side effects as other medications that block dopamine receptors, such as drowsiness and dizziness.
Rebfon-DSR (Rabeprazole) treats duodenal ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome, a condition where the stomach produces too much acid. Domperidone stops the possibility of vomiting and other related problems.
Synergistic Effects of Rabeprazole Sodium and Domperidone SR
Rabeprazole and domperidone DSR capsules are used to treat GERD, stomach disturbance, gaseous problems due to fast foods and ulcers, effective in digestion improvement, and appetite problems.
Pharmacokinetics and Formulation of Rabeprazole Sodium and Domperidone SR Capsules
Rabeprazole and Domperidone Sustained Release capsules are a fixed-dose combination of two drugs that are used to treat gastroesophageal reflux disease (GERD). It is a condition in which stomach acid backs up into the esophagus, causing heartburn, acid regurgitation, and other symptoms.
The pharmacokinetics of rabeprazole sodium and domperidone SR capsules are as follows:
- Rabeprazole sodium is speedily absorbed in the small intestine after oral administration. Then, it is converted to its active form, rabeprazole, in the stomach. The biological half-life of Rabeprazole is 30 min to 1 hour, however, the peak plasma concentration of Rabeprazole is reached within 3.5 hours after administration.-(Ref.)
- Domperidone sustained release is an SR formulation of domperidone. It is released slowly from the capsule over a period of 8 to 12 hours. The peak plasma concentration of domperidone is reached within 2 to 3 hours after administration.
The design of the formulation of Rabeprazole and Domperidone SR capsules is such a way to provide controlled release of domperidone into the bloodstream, and Rabeprazole is allowed to release immediately. Capsules contain enteric-coated pellets of Domperidone as sustained release while Rabeprazole pellets as an immediate release form. The enteric coating prevents the drugs from being released into the stomach.
The combination of Rabeprazole Sodium and Domperidone SR is highly effective in treating GERD. In several studies, it is found that this combination reduces heartburn, acid regurgitation, and other associated symptoms of GERD.
Here is some additional information about the pharmacokinetics and formulation of rabeprazole sodium and domperidone SR capsules:
- The bioavailability of rabeprazole sodium is about 50%. The bioavailability of domperidone SR is about 70%.
- The half-life of rabeprazole sodium is about 1.5 hours. The half-life of domperidone is about 7 hours.
- Rabeprazole sodium and domperidone SR capsules are metabolized in the liver and excreted in the urine.
Indications for Rabeprazole Sodium and Domperidone SR Combination:
There are many symptoms for which Rabeprazole and Domperidone SR capsules are indicated. Following are common of them:
- Gastroesophageal reflux disease (GERD)
- Stomach acid
- Stomach gas
- Heartburn
- Vomiting tendency
Dosage Regimen and Administration Guidelines
The optimal dose of Rabeprazole Sodium and Domperidone SR capsule is one capsule a day in the morning. Usually, it is prescribed in the morning before a meal.
Clinical Studies and Evidence-Based Results
A randomized control study comparing the efficacy and safety of Rabeprazole monotherapy vs. rabeprazole and Domperidone combination in patients with Laryngopharyngeal reflux disease at a tertiary care center was carried out by Kiran Thimmarayappa, Musarrat Feshan, and Preetham A P.
In that study, 54 patients with LPR were evaluated to determine the efficacy and safety of Rabeprazole monotherapy vs Rabeprazole and Domperidone combination therapy. The study was divided into two groups where 27 patients Group A was given Rabperazole 20mg + Domperidone 30 mg, and Group B was given Rabeprazole 20 mg, the dose given once a day for 4 weeks, then the results were assessed.
Results: The conclusion of the study was that rabeprazole with Domperidone is a better choice to treat the symptoms of Laryngopharyngeal Reflux disease, however, both drugs were found efficacious and well tolerated.
Potential Side Effects and Interactions
Rabeprazole and Domperidone SR capsules are found to be well tolerated by most of the patients, however, some potential side effects of these medications are possible, which are listed below:
- Headache
- Nausea
- Stomach pain
- Diarrhea
- Dry mouth
- Constipation
- Dizziness
- Fatigue
- Rash
The serious side effects of Rabeprazole And Domperidone SR capsules are very rarely observed, they can include:
- Stomach perforation
- Liver damage
- Kidney damage
- Low levels of magnesium in the blood
- Long QT syndrome (a heart rhythm disorder)
- Allergic reactions
Drug Interactions and Precautionary Measures for Rabeprazole and Domperidone SR Capsules are listed. The possible drug interaction with this combination is given below:
- The use of Antacids, H2 blockers, and other PPIs may reduce the effectiveness of rabeprazole.
- Drugs like Ketoconazole, itraconazole, and other antifungals may increase the blood levels of rabeprazole and cause adverse effects.
- Warfarin, clopidogrel, and other blood thinners may increase the risk of bleeding with Rabeprazole, always consult your doctor before using these drugs simultaneously.
- Domperidone may interact with drugs that affect the heart rhythm, such as quinidine, amiodarone, sotalol, and erythromycin. So avoid self-medication with these medicines
- Domperidone may also interact with drugs that affect the brain, such as antidepressants, antipsychotics, and opioids.
SHORT DESCRIPTION
Brand Name: REBFON-DSR
Dosage Form: Capsules
COMPOSITION:
Each hard gelatin capsule contains:
Rabeprazole 20mg.+Domperidone SR 30mg.
Packing: 10*10 alu alu
MRP: 90.00 PER 10 CAPSULES.
Also Available;
Pantafon-DSR (Pantoprazole 40mg+Domperidone 30 mg SR Capsules)
Fonvital Plus: Ginseng with Multivitamins, Minerals & Antioxidants capsules
Mecome-Alpha: Methylcobalamin alpha-lipoic acid pyridoxine Hydrochloride, folic acid, and Thiamine Mononitrate
DOWN-A SUSPENSION: Aceclofenac and Paracetamol suspension
KUFTIPS SYRUP: An Ayurvedic cough syrup
Itco-200: Itraconazole capsules 200 mg
FAQ
What is Rebfon-DSR used for?
Rebfon-DSR is a combination medication used to treat various gastrointestinal disorders, including acid reflux, heartburn, indigestion, and stomach ulcers. It works by reducing acid production in the stomach and improving digestion.
How does Rebfon-DSR work?
Rebfon-DSR contains two active ingredients: Rabeprazole Sodium and Domperidone. Rabeprazole Sodium is a proton pump inhibitor (PPI) that reduces acid production in the stomach. Domperidone is a prokinetic agent that improves the movement of food through the digestive tract.
What are the potential side effects of Rebfon-DSR?
Common side effects of Rebfon-DSR include headache, nausea, diarrhea, and constipation.
How should I take Rebfon-DSR?
Rebfon-DSR is typically taken once a day, usually in the morning before a meal. It’s important to follow the dosage instructions provided by your doctor or pharmacist. Do not take more or less than the prescribed amount, and do not stop taking the medication without consulting your doctor. Avoid unnecessary use of this medication without doctor’s advice.
What is the MRP of the Rebfon-DSR capsule?
The MRP of Rebfon-DSR is Rs. 90/- per strip.
References:
- Gastroesophageal reflux disease (GERD):-[Mayo Clinic]
- Rabeprazole Sodium Delayed-Release Tablets, for oral use Initial U.S. Approval: 1999 [https://www.accessdata.fda(.gov)]
- Rabeprazole SODIUM [WebMD]
- Rabeprazole [Go-Drugbank(online)]
- Diagram of the mechanism of action of rabeprazole sodium-MDPI [https://www.mdpi.com/1999-4923/13/2/259/reprints]
- Domperidone-[Drugs(.com)]
- Domperidone-GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, SERIES #9 [Practicalgastro(.com]
- Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions [PubMed]
- Pharmacokinetics and dose proportionality of domperidone in healthy volunteers: Y C Huang, J L Colaizzi, R H Bierman, R Woestenborghs, J J Heykants, PMID: 3793955, DOI: 10.1002/j.1552-4604.1986.tb02962.x [NIH- National Library of Medicines]
- A randomized control study comparing efficacy and safety of Rabeprazole monotherapy Vs Rabeprazole and Domperidone combination in patients with Laryngopharyngeal reflux disease at a tertiary care center; [IOSR Journal of Dental and Medical Sciences]
Disclaimer:
Disclaimer: This site’s information and articles are for educational purposes only. The information given here should not be used to diagnose or treat any health problem or disease without expert advice. The advice of a qualified medical practitioner should always be sought for medical examination and treatment.
Reviewed by;
Dr. Yogesh Chaudhary (B. Pharma)
Senior Pharmacist at S.N. Medical College, Agra-(UP)